Marcos Custódio1, Bruno Tavares Sedassari2, Albina Altemani3, Maria Fernanda Setúbal Destro Rodrigues2, Fábio Daumas Nunes4, Suzana Cantanhede Orsini Machado de Sousa4. 1. Universidade de São Paulo/USP, Faculdade de Odontologia, Av. Professor Lineu Prestes, 2227, Cidade Universitária, São Paulo, SP, 05508-000, Brasil. marcosjcustodio@usp.br. 2. Universidade Nove de Julho/UNINOVE, São Paulo, SP, Brasil. 3. Universidade Estadual de Campinas/UNICAMP, Faculdade de Ciências Médicas, Campinas, SP, Brasil. 4. Universidade de São Paulo/USP, Faculdade de Odontologia, Av. Professor Lineu Prestes, 2227, Cidade Universitária, São Paulo, SP, 05508-000, Brasil.
Abstract
PURPOSE: To investigate the expression of upstream and downstream targets of mTOR signalling pathway in the secretory carcinoma of salivary gland origin (SCsg). METHODS: Seven cases of secretory carcinoma diagnosed by a combination of immunohistochemistry and/or molecular testing were retrieved from our pathology files. For comparison purposes, 27 other salivary carcinomas were selected. Immunohistochemical staining was performed against phospho-Akt, PTEN, phospho-mTOR, phospho-4E-BP, eIF4E and phospho-S6 ribosomal protein. RESULTS: With the exception of Akt, all the other proteins were present at some level in the SCsg and in other salivary carcinomas. PTEN was diffusely expressed in 57.1% of SCsg, but only in 14.8% of other salivary carcinomas. mTOR is expressed in more than half of the cases both for SCsg and other salivary tumour types. Most cases of SCsg showed negative expression for S6 ribosomal protein (71.4%) and 4E-BP1 (57.1%). For both groups evaluated, eIF4E was the most expressed protein. CONCLUSION: SCsg shows different expression patterns for the mTOR signalling molecules, but only eIF4E was highly expressed. This may suggest alternative signalling pathways other than Akt and mTOR in this group of tumours.
PURPOSE: To investigate the expression of upstream and downstream targets of mTOR signalling pathway in the secretory carcinoma of salivary gland origin (SCsg). METHODS: Seven cases of secretory carcinoma diagnosed by a combination of immunohistochemistry and/or molecular testing were retrieved from our pathology files. For comparison purposes, 27 other salivary carcinomas were selected. Immunohistochemical staining was performed against phospho-Akt, PTEN, phospho-mTOR, phospho-4E-BP, eIF4E and phospho-S6 ribosomal protein. RESULTS: With the exception of Akt, all the other proteins were present at some level in the SCsg and in other salivary carcinomas. PTEN was diffusely expressed in 57.1% of SCsg, but only in 14.8% of other salivary carcinomas. mTOR is expressed in more than half of the cases both for SCsg and other salivary tumour types. Most cases of SCsg showed negative expression for S6 ribosomal protein (71.4%) and 4E-BP1 (57.1%). For both groups evaluated, eIF4E was the most expressed protein. CONCLUSION: SCsg shows different expression patterns for the mTOR signalling molecules, but only eIF4E was highly expressed. This may suggest alternative signalling pathways other than Akt and mTOR in this group of tumours.
Entities:
Keywords:
Head and neck; Salivary gland tumours; Secretory carcinoma; mTOR pathway
Authors: Wook Jin; Byung-Chul Kim; Cristina Tognon; Ho-Jae Lee; Sejal Patel; Chris L Lannon; John M Maris; Timothy J Triche; Poul H B Sorensen; Seong-Jin Kim Journal: Proc Natl Acad Sci U S A Date: 2005-10-28 Impact factor: 11.205
Authors: Gregor Krings; Nancy M Joseph; Gregory R Bean; David Solomon; Courtney Onodera; Eric Talevich; Iwei Yeh; James P Grenert; Elizabeth Hosfield; Emily D Crawford; Richard C Jordan; Annemieke van Zante; Charles Zaloudek; Sandra J Shin; Yunn-Yi Chen Journal: Mod Pathol Date: 2017-05-26 Impact factor: 7.842